Published ahead of print on February 28, 2008, doi:10.1164/rccm.200708-1283OC Am. J. Respir. Crit. Care Med., Volume 177, Number 10, May 2008, 1156-1163 A more recent version of this article appeared on May 15, 2008
Submitted on August 30, 2007 Determinants of the Survival Benefit of Lung Transplantation in COPD PatientsGabriel Thabut1*,1 Service de pneumologie B et transplantation pulmonaire, Hopital Bichat, Paris, France; INSERM U738, Paris, France, 2 Departement d'epidemiologie, de biostatistiques et de recherche clinique, Hopital Bichat, Paris, France; INSERM U738, Paris, France, 3 Division of Pulmonary and Critical Care Medicine, Department of Medicine, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA, 4 Service de chirurgie thoracique et vasculaire, Hopital Bichat, Paris, France, 5 Service de pneumologie B et transplantation pulmonaire, Hopital Bichat, Paris, France, 6 INSERM U717, Paris, France; Departement de Biostatistique et Informatique Medicale, Hopital Saint-Louis, Paris, France * To whom correspondence should be addressed. E-mail: g.thabut{at}bch.aphp.fr.
Rationale: Despite chronic obstructive pulmonary disease being the first indication for lung transplantation, the benefit of the procedure in terms of survival remains debated. Objective: To estimate the determinants of the survival benefit of lung transplantation in patients with chronic obstructive pulmonary disease. Methods: Using information from the United Network for Organ Sharing database on 8182 patients, we developed an approach based on numerical simulations to estimate the survival effect of lung transplantation. Measurements and main results: the main outcome measure was the difference between median survival with transplantation and that without transplantation measured from registration on the list. Survival benefit was greater with double than with single lung transplantation (mean difference of 307 days [95% CI: 217-523]). With double lung transplantation, 44.6% of patients would gain 1 year or more, 29.4% would gain or lose less than 1 year, and 26% would lose 1 year or more. Major determinants of the survival effect of transplantation were systolic pulmonary artery pressure, FEV1, body mass index, exercise capacity, functional status and the need for continuous mechanical ventilation or oxygen. For instance, 79% of patients with FEV1 less than 16% of the predicted value would gain one year or more with double lung transplantation as compared with only 11% of patients with FEV1 more than 25%. Conclusions: We identified several factors associated with the survival benefit of lung transplantation. External validation of our models is required before translating these results into clinical practice. Key words: Lung transplantation, COPD, prognosis
This article has been cited by other articles:
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||